New stem cell harvest method tested for bone marrow cancer

NCT ID NCT03909412

Recruiting now Disease control Sponsor: Hackensack Meridian Health Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated May 20, 2026 · Updated 15 times

Summary

This early-phase study tests a drug combination (carfilzomib, cyclophosphamide, dexamethasone, and G-CSF) to safely collect stem cells for transplant in people with multiple myeloma. About 18 participants will receive different doses to find the safest and most effective level. The goal is to improve stem cell collection while controlling the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Hackensack Meridian Health - John Theurer Cancer Center
RECRUITING

Hackensack, New Jersey, 07601, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

MULTIPLE MYELOMA